Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors. [electronic resource]
Producer: 20090403Description: S95-S106 p. digitalISSN:- 1557-9190
- Benzamides
- Clinical Trials as Topic
- Dasatinib
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Piperazines -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrimidines -- administration & dosage
- Thiazoles -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.